Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 9 September 1994:
Vol. 265. no. 5178, pp. 1587 - 1590
DOI: 10.1126/science.7915856
Prev | Table of Contents | Next

Articles

Science, Vol 265, Issue 5178, 1587-1590
Copyright © 1994 by American Association for the Advancement of Science

articles

Reduced rate of disease development after HIV-2 infection as compared to HIV-1

R Marlink, P Kanki, I Thior, K Travers, G Eisen, T Siby, I Traore, CC Hsieh, MC Dia, EH Gueye, and al. et

Department of Cancer Biology, Harvard School of Public Health, Boston, MA 02115.

Human immunodeficiency virus type-2 (HIV-2) is a close relative of the prototype acquired immunodeficiency syndrome (AIDS) virus, HIV-1. HIV-2 is biologically similar to HIV-1, but information is lacking concerning clinical outcomes of HIV-2-infected individuals. From 1985 to 1993, a prospective clinical study was conducted in women with HIV-2 and HIV-1 infection to determine and compare rates of disease development. HIV-1-infected women had a 67% probability of AIDS-free survival 5 years after seroconversion in contrast with 100% for HIV-2-infected women. In addition to having significantly less HIV-related disease outcome in HIV-2 enrollees compared to HIV-1 enrollees, the rate of developing abnormal CD4+ lymphocyte counts with HIV-2 infection was also significantly reduced. This natural history study demonstrates that HIV-2 has a reduced virulence compared to HIV-1.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Antiretroviral Drug Resistance in Human Immunodeficiency Virus Type 2.
M. L. Ntemgwa, T. d. Toni, B. G. Brenner, R. J. Camacho, and M. A. Wainberg (2009)
Antimicrob. Agents Chemother. 53, 3611-3619
   Full Text »    PDF »
Nucleoside and Nucleotide Analogs Select in Culture for Different Patterns of Drug Resistance in Human Immunodeficiency Virus Types 1 and 2.
M. L. Ntemgwa, T. d. Toni, B. G. Brenner, M. Oliveira, E. L. Asahchop, D. Moisi, and M. A. Wainberg (2009)
Antimicrob. Agents Chemother. 53, 708-715
   Abstract »    Full Text »    PDF »
Gag-Specific CD4+ T-Cell Frequency Is Inversely Correlated with Proviral Load and Directly Correlated with Immune Activation in Infection with Human Immunodeficiency Virus Type 2 (HIV-2) but Not HIV-1.
R. B. Foxall, C. S. Cortesao, A. S. Albuquerque, R. S. Soares, R. M. M. Victorino, and A. E. Sousa (2008)
J. Virol. 82, 9795-9799
   Abstract »    Full Text »    PDF »
Higher Homologous and Lower Cross-Reactive Gag-Specific T-Cell Responses in Human Immunodeficiency Virus Type 2 (HIV-2) Than in HIV-1 Infection.
W. Jennes, M. Camara, T. Dieye, S. Mboup, and L. Kestens (2008)
J. Virol. 82, 8619-8628
   Abstract »    Full Text »    PDF »
Human Immunodeficiency Virus Types 1 and 2 Exhibit Comparable Sensitivities to Zidovudine and Other Nucleoside Analog Inhibitors In Vitro.
R. A. Smith, G. S. Gottlieb, D. J. Anderson, C. L. Pyrak, and B. D. Preston (2008)
Antimicrob. Agents Chemother. 52, 329-332
   Abstract »    Full Text »    PDF »
Dendritic Cells Are Less Susceptible to Human Immunodeficiency Virus Type 2 (HIV-2) Infection than to HIV-1 Infection.
M. G. Duvall, K. Lore, H. Blaak, D. A. Ambrozak, W. C. Adams, K. Santos, C. Geldmacher, J. R. Mascola, A. J. McMichael, A. Jaye, et al. (2007)
J. Virol. 81, 13486-13498
   Abstract »    Full Text »    PDF »
Nef-Mediated Enhancement of Virion Infectivity and Stimulation of Viral Replication Are Fundamental Properties of Primate Lentiviruses.
J. Munch, D. Rajan, M. Schindler, A. Specht, E. Rucker, F. J. Novembre, E. Nerrienet, M. C. Muller-Trutwin, M. Peeters, B. H. Hahn, et al. (2007)
J. Virol. 81, 13852-13864
   Abstract »    Full Text »    PDF »
Efficient Thymopoiesis Contributes to the Maintenance of Peripheral CD4 T Cells during Chronic Human Immunodeficiency Virus Type 2 Infection.
D. Gautier, S. Beq, C. S. Cortesao, A. E. Sousa, and R. Cheynier (2007)
J. Virol. 81, 12685-12688
   Abstract »    Full Text »    PDF »
Comparison of Heterologous Neutralizing Antibody Responses of Human Immunodeficiency Virus Type 1 (HIV-1)- and HIV-2-Infected Senegalese Patients: Distinct Patterns of Breadth and Magnitude Distinguish HIV-1 and HIV-2 Infections.
S. K. Rodriguez, A. D. Sarr, A. MacNeil, S. Thakore-Meloni, A. Gueye-Ndiaye, I. Traore, M. C. Dia, S. Mboup, and P. J. Kanki (2007)
J. Virol. 81, 5331-5338
   Abstract »    Full Text »    PDF »
Direct Evidence of Lower Viral Replication Rates In Vivo in Human Immunodeficiency Virus Type 2 (HIV-2) Infection than in HIV-1 Infection.
A. MacNeil, A. D. Sarr, J.-L. Sankale, S. T. Meloni, S. Mboup, and P. Kanki (2007)
J. Virol. 81, 5325-5330
   Abstract »    Full Text »    PDF »
Cross-Clade Inhibition of Recombinant Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus SIVcpz Reverse Transcriptases by RNA Pseudoknot Aptamers.
D. M. Held, J. D. Kissel, S. J. Thacker, D. Michalowski, D. Saran, J. Ji, R. W. Hardy, J. J. Rossi, and D. H. Burke (2007)
J. Virol. 81, 5375-5384
   Abstract »    Full Text »    PDF »
Rate of Increase in Circulating IL-7 and Loss of IL-7R{alpha} Expression Differ in HIV-1 and HIV-2 Infections: Two Lymphopenic Diseases with Similar Hyperimmune Activation but Distinct Outcomes.
A. S. Albuquerque, C. S. Cortesao, R. B. Foxall, R. S. Soares, R. M. M. Victorino, and A. E. Sousa (2007)
J. Immunol. 178, 3252-3259
   Abstract »    Full Text »    PDF »
Presenting Plasma HIV RNA Level and Rate of CD4 T-Cell Decline.
G. S. Gottlieb, S. E. Hawes, D. C. Nickle, J. T. Herbeck, N. B. Kiviat, J. I. Mullins, and P. S. Sow (2007)
JAMA 297, 805
   Full Text »    PDF »
Natural Polymorphisms in the Human Immunodeficiency Virus Type 2 Protease Can Accelerate Time to Development of Resistance to Protease Inhibitors.
M. Ntemgwa, B. G. Brenner, M. Oliveira, D. Moisi, and M. A. Wainberg (2007)
Antimicrob. Agents Chemother. 51, 604-610
   Abstract »    Full Text »    PDF »
Quantitative Detection of Plasma Human Immunodeficiency Virus Type 2 Subtype A RNA by the Nuclisens EasyQ Assay (Version 1.1).
B. Rodes, J. Sheldon, C. Toro, L. Cuevas, E. Perez-Pastrana, I. Herrera, and V. Soriano (2007)
J. Clin. Microbiol. 45, 88-92
   Abstract »    Full Text »    PDF »
Increased Frequency of Circulating CCR5+ CD4+ T Cells in Human Immunodeficiency Virus Type 2 Infection.
R. Soares, R. Foxall, A. Albuquerque, C. Cortesao, M. Garcia, R. M. M. Victorino, and A. E. Sousa (2006)
J. Virol. 80, 12425-12429
   Abstract »    Full Text »    PDF »
Rapid Viral Decay in Simian Immunodeficiency Virus-Infected Macaques Receiving Quadruple Antiretroviral Therapy.
E. Brandin, R. Thorstensson, S. Bonhoeffer, and J. Albert (2006)
J. Virol. 80, 9861-9864
   Abstract »    Full Text »    PDF »
Genomic Sites of Human Immunodeficiency Virus Type 2 (HIV-2) Integration: Similarities to HIV-1 In Vitro and Possible Differences In Vivo..
A. MacNeil, J.-L. Sankale, S. T. Meloni, A. D. Sarr, S. Mboup, and P. Kanki (2006)
J. Virol. 80, 7316-7321
   Abstract »    Full Text »    PDF »
Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.
B. Rodes, J. Sheldon, C. Toro, V. Jimenez, M. A. Alvarez, and V. Soriano (2006)
J. Antimicrob. Chemother. 57, 709-713
   Abstract »    Full Text »    PDF »
Natural Killer Cell Function Is Well Preserved in Asymptomatic Human Immunodeficiency Virus Type 2 (HIV-2) Infection but Similar to That of HIV-1 Infection When CD4 T-Cell Counts Fall.
S. V. Nuvor, M. van der Sande, S. Rowland-Jones, H. Whittle, and A. Jaye (2006)
J. Virol. 80, 2529-2538
   Abstract »    Full Text »    PDF »
Human immunodeficiency virus types 1 and 2 have different replication kinetics in human primary macrophage culture.
D. Marchant, S. J. D. Neil, and A. McKnight (2006)
J. Gen. Virol. 87, 411-418
   Abstract »    Full Text »    PDF »
Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation.
Y. Shi, E. Brandin, E. Vincic, M. Jansson, A. Blaxhult, K. Gyllensten, L. Moberg, C. Brostrom, E. M. Fenyo, and J. Albert (2005)
J. Gen. Virol. 86, 3385-3396
   Abstract »    Full Text »    PDF »
The Glutamine-rich Region of the HIV-1 Tat Protein Is Involved in T-cell Apoptosis.
G. R. Campbell, E. Pasquier, J. Watkins, V. Bourgarel-Rey, V. Peyrot, D. Esquieu, P. Barbier, J. de Mareuil, D. Braguer, P. Kaleebu, et al. (2004)
J. Biol. Chem. 279, 48197-48204
   Abstract »    Full Text »    PDF »
Cervical Neoplasia and Highly Active Antiretroviral Therapy.
L. F. Xi and N. B. Kiviat (2004)
J Natl Cancer Inst 96, 1051-1053
   Full Text »    PDF »
Host Determinants in HIV Infection and Disease: Part 1: Cellular and Humoral Immune Responses.
C. M. Hogan and S. M. Hammer (2001)
Ann Intern Med 134, 761-776
   Abstract »    Full Text »    PDF »
Designing HIV Vaccination Policies: Subtypes and Cross-Immunity.
T. C. Porco and S. M. Blower (1998)
Interfaces 28, 167-190
   Abstract »    PDF »
The Human Immunodeficiency Virus Type 1 (HIV-1) Vpu Protein Interferes with an Early Step in the Biosynthesis of Major Histocompatibility Complex (MHC) Class I Molecules.
T. Kerkau, I. Bacik, J. R. Bennink, J. W. Yewdell, T. Hunig, A. Schimpl, and U. Schubert (1997)
J. Exp. Med. 185, 1295-1306
   Abstract »    Full Text »    PDF »
The Emerging Genetic Diversity of HIV: The Importance of Global Surveillance for Diagnostics, Research, and Prevention.
D. J. Hu, T. J. Dondero, M. A. Rayfield, J. R. George, G. Schochetman, H. W. Jaffe, C.-C. Luo, M. L. Kalish, B. G. Weniger, C.-P. Pau, et al. (1996)
JAMA 275, 210-216
   Abstract »    PDF »
Natural protection against HIV-1 infection provided by HIV-2.
K Travers, S Mboup, R Marlink, A Gueye-Nidaye, T Siby, I Thior, I Traore, A Dieng-Sarr, J. Sankale, C Mullins, et al. (1995)
Science 268, 1612-1615
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)